<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336898">
  <stage>Registered</stage>
  <submitdate>5/05/2011</submitdate>
  <approvaldate>8/07/2011</approvaldate>
  <actrnumber>ACTRN12611000707965</actrnumber>
  <trial_identification>
    <studytitle>Comparison of minimally invasive cardiac output monitors in the detection of hypovolaemia in awake volunteers.</studytitle>
    <scientifictitle>Awake volunteer study of controlled hypovolaemia investigating the ability of minimially invasive cardiac output  monitors (LiDCO Rapid, FloTRAC, Oesophageal doppler and USCOM) in detecting known blood loss.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypovolaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will be monitored with an arterial line (connected to LiDCO rapid and FloTrac monitors), oesophageal doppler and suprasternal doppler.
Participants will be venesected incrementally to a 20% blood loss.
The venesection will be a once only event lasting over approximately 2 hours..
FloTrac and LiDCO are arterial pulse wave contour analysis devices that derive information about the cardiovascular system from the nature of the observered arterial waveform.
Oesophageal doppler uses ultrasound to assess blood flow in the descending aorta and interperets this flow based on the patients age and body habitus.
Suprasternal doppler (USCOM) also uses doppler to assess flow but from the suprasternal notch rather than from the oesophagus.</interventions>
    <comparator>All participants will be monitored with all the monitors of cardiovascular status being studied, effectively acting as their own control.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ability of monitor (LiDCO rapid, FloTRAC, Oesophageal doppler and USCOM) to detect a known 10% blood loss.</outcome>
      <timepoint>At time of 10% blood loss</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Ability of above monitors to detect incremental blood loss.</outcome>
      <timepoint>5 minutely assessment of fluid status and monitor output up to 2 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Isofuran and isoprostane levels</outcome>
      <timepoint>assessed at each incremental level of venesection</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy adult, not taking cardiovascularly active medication</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Cardiovascular medications
abnormal cardiovascular history or examination</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Consenting anaesthetists able to give informed consent will be recruited to the trial.
All participants will be incrementally venesected and have all 4 monitors of cardiac output used</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>6160</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Fremantle Hospital</primarysponsorname>
    <primarysponsoraddress>Alma St,
Fremantle, WA 6160</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Fremantle Hospital</fundingname>
      <fundingaddress>Alma St, 
Fremantle, WA 6160</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Tomas Corcoran</othercollaboratorname>
      <othercollaboratoraddress>Department of Anaesthesia
Royal Perth Hospital
Perth WA 6000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Trevor Mori</othercollaboratorname>
      <othercollaboratoraddress>University of Western Australia
Nedlands WA 6009</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>this study seeks to determine if minimially invasive monitors can detect blood loss in awake patients.  Our hypothesis is that the monitors will be able to detect a known blood loss of 10% of estimated blood volume. 
We will test this by bleeding volunteers a known amount of blood and then looking to see if the monitors detect this blood loss.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Metropolitan Area Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>Alma St,
Fremantle, WA 6160</ethicaddress>
      <ethicapprovaldate>1/03/2011</ethicapprovaldate>
      <hrec>1/10/0421</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Edmond O'Loughlin</name>
      <address>Department of Anaesthesia
Fremantle Hospital
Fremantle, WA 6160</address>
      <phone>+ 61 8 9431 3333</phone>
      <fax />
      <email>edmond.o'loughlin@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Edmond O'Loughlin</name>
      <address>Department of Anaesthesia
Fremantle Hospital
Fremantle, WA 6160</address>
      <phone>+ 61 8 9431 3333</phone>
      <fax />
      <email>edmond.o'loughlin@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Edmond O'Loughlin</name>
      <address>Department of Anaesthesia
Fremantle Hospital
Fremantle, WA 6160</address>
      <phone>+ 61 8 9431 3333</phone>
      <fax />
      <email>edmond.o'loughlin@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>